Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy

Abstract

There is no established immunological marker of multiple sclerosis activity, which reflects the poor understanding of the immunopathogenesis of multiple sclerosis. Passive measurement of the levels of soluble inflammatory markers, whose half lives are usually measured in minutes and hours, can only indicate the extent of instantaneous inflammation, which is known to fluctuate in multiple sclerosis. We favour measurement of immune responses in vitro. As healthy individuals have T cell reactivities to myelin proteins that are postulated to be pathogenic in multiple sclerosis,^1,2 we prefer non-antigen specific mitogen and recall antigen assays as immunological markers. We illustrate their use in the treatment of 27 patients with multiple sclerosis using a pulse of humanised anti-lymphocyte (CD52) antibody that caused prolonged T cell depletion. The mitogen-induced proliferation, and secretion of IFN-g, from peripheral blood mononuclear cells in vitro was significantly reduced after treatment, suggesting that immune responses had been modulated. Such observations will only gain credence as an outcome measure if they are shown to correlate with clinical or radiological measures of multiple sclerosis activity. Perhaps more importantly, aspects of the pathogenesis of multiple sclerosis may be revealed by close immunological surveillance of patients undergoing experimental treatments.

Keywords

Campath-1H multiple sclerosis T-helper 1 T-helper 2 peripheral blood mononuclear cells Graves'autoimmune thyroiditis

Get full access to this article

View all access options for this article.

References

Pette M et al. (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals . Neurology 40: 1770-1776 .

vanNoort JM et al. (1993) Minor myelin proteins can be major targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects . J Neuroimmunol 46: 67-72 .

Rudge P et al. (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis . Journal of Neurology Neurosurgery and Psychiatry 52: 559-565 .

Kastrukoff LF et al. (1991) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunoligic evaluation . Neurology 41: 1936-1941 .

Daser A , Meissner N , Herz U , Renz H. (1995) Role and modulation of T-cell cytokines in allergy . Current Opinion in Immunology 7: 762-770 .

McHugh SM et al. (1995) Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy . Clin Exp Allergy 25: 828-838 .

Riechmann L , Clark M , Waldmann H , Winter G. (1988) Reshaping human antibodies for therapy . Nature 332: 323-327 .

Isaacs JD et al. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis . Lancet 340: 748-752 .

[published erratum appears in Lancet 1994 Aug 13;344(8920): 486-486 ].

10.

Rowan WC , Hale G , Tite JP , Brett SJ. (1995) Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes . International Immunology 7: 69-77 .

11.

Hirsch RL , Panitch HS , Johnson KP. (1985) Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro . J Clin Immunol 5: 386-389 .

12.

Papiha SS , Boddy J , Roberts DF , Bates D. (1989) PHA-induced interferon in multiple sclerosis: Association between gamma interferon and clinical and genetical variables . Acta Neurologica Scandinavica 80: 145-150 .

13.

Philippe J et al. (1996) In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis . Clinical Neurology and Neurosurgery 98: 286-290 .

14.

Racke MK et al. (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease . J Exp Med 180: 1961-1966 .

15.

Genain CP et al. (1996) Late complications of immune deviation therapy in a nonhuman primate . Science 274: 2054-2057 .

16.

Hafler DA et al. (1986) Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12 . Neurology 36: 777-784 .

17.

Ricci M , Matucci A , Rossi O. (1997) Source of IL-4 able to induce the development of TH2-like cells . Clinical and Experimental Allergy 27: 488-500 .

18.

Tomasevic L , Nikolic J , Lukic M , Levic Z. (1990) Circulating autoantibodies in multiple sclerosis . Neurologija 39: 157-161 .

19.

Van Oosten BW et al. (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cMT412; results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial . Neurology 49: 351-357 .

20.

Hafler DA , Weiner HL. (1988) Immunosuppression with monoclonal antibodies in multiple sclerosis . Neurology 38: 42-47 .

21.

Brod SA et al. (1996) Interferon-beta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis . Neurology 46: 1633-1638 .